Unlike Tuberculosis (TB),
Mycobacterium abscessus lung disease is a highly drug-resistant bacterial infection with no reliable treatment options. De novo
M. abscessus drug discovery is urgently needed but is hampered by the bacterium’s extreme drug resistance profile, leaving the current drug pipeline underpopulated.
[...] Read more.
Unlike Tuberculosis (TB),
Mycobacterium abscessus lung disease is a highly drug-resistant bacterial infection with no reliable treatment options. De novo
M. abscessus drug discovery is urgently needed but is hampered by the bacterium’s extreme drug resistance profile, leaving the current drug pipeline underpopulated. One proposed strategy to accelerate de novo
M. abscessus drug discovery is to prioritize screening of advanced TB-active compounds for anti-
M. abscessus activity. This approach would take advantage of the greater chance of homologous drug targets between mycobacterial species, increasing hit rates. Furthermore, the screening of compound series with established structure–activity-relationship, pharmacokinetic, and tolerability properties should fast-track the development of in vitro anti-
M. abscessus hits into lead compounds with in vivo efficacy. In this review, we evaluated the effectiveness of this strategy by examining the literature. We found several examples where the screening of advanced TB chemical matter resulted in the identification of anti-
M. abscessus compounds with in vivo proof-of-concept, effectively populating the
M. abscessus drug pipeline with promising new candidates. These reports validate the screening of advanced TB chemical matter as an effective means of fast-tracking
M. abscessus drug discovery.
Full article
